ArticleJMIR formative research2025
A Mobile App to Enhance Awareness of Vaccination in Adults With Psoriasis and Atopic Dermatitis: Development and Preliminary Evaluation Study.
Article in JMIR formative research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with psoriasis and atopic dermatitis are at increased risk of several vaccine-preventable diseases. Despite this increased susceptibility to infections, vaccination uptake in adults with psoriasis and atopic dermatitis, especially if treated with biologics and other systemic immunomodulators, is insufficient. As mobile health technologies may support behavior change, a mobile app called DermatoVax was developed to raise awareness of immunization in adult patients with psoriasis and atopic dermatitis.
objectiveThis paper aims to describe the processes of development of the DermatoVax app and its initial evaluation in terms of technical verification and physicians' quality rating.
methodsThe app was conceived in a user-centered fashion. Its core component was the vaccine checker, which allows the app to produce a sharable list of recommended vaccines, immunization timings, and eventual precautions from a short set of input data. App prototypes were extensively piloted, and feedback from potential end users was obtained to refine the app content. The readability of the textual narratives was measured using the Italian-specific Gulpease index, which ranges from 0 to 100, where 100 indicates the best readability. The quality of the final version was evaluated by 46 medical doctors (n=29, 63% dermatologists and n=17, 37% public health physicians) using a validated Italian user version of the Mobile App Rating Scale (uMARS).
resultsIterative steps during the app development process allowed us to increase its user-friendliness and comprehensibility. Proper functioning of the checker was confirmed through the correct and complete generation of recommended vaccine lists for 50 mock patients with psoriasis and atopic dermatitis. An overall Gulpease index of 41.0 was observed for the final textual narratives, suggesting acceptable readability properties for patients with a high school diploma. Of a maximum of 5 points, the average uMARS score was 4.22 (SD 0.49). Ratings provided by dermatologists (mean 4.28, SD 0.48) were similar (P=.33) to those provided by public health physicians (mean 4.12, SD 0.51). However, the mean uMARS scores for the quality dimensions of aesthetics (3.88, SD 0.78) and engagement (3.89, SD 0.68) were lower than those for information (4.64, SD 0.42) and functionality (4.47, SD 0.46), suggesting margins for improvement. The app's perceived impact was notably high, with over 80% of physicians agreeing that its use would significantly improve patient awareness (39/46, 85%) and knowledge (41/46, 89%) of vaccination, leading to increased vaccination uptake (37/46, 80%).
conclusionsDermatoVax is a promising tool to raise awareness of immunization in adult patients with psoriasis and atopic dermatitis. Further assessment of the app, such as its effectiveness in increasing vaccination uptake, is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.